Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer
Open Access
- 1 January 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 2, 10
Abstract
Pancreatic ductal adenocarcinoma (PDA) is a highly chemoresistant and metastatic disease with a dismal 5-year survival rate of 6%. More effective therapeutic targets and approaches are urgently needed to tackle this devastating disease. The base excision repair (BER) pathway has been identified as a predictor of therapeutic response, prognostic factor, and therapeutic target in a variety of cancers. This review will discuss our current understanding of BER in PDA and its potential to improve PDA treatment.Keywords
This publication has 142 references indexed in Scilit:
- Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicityNucleic Acids Research, 2013
- Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repairNucleic Acids Research, 2013
- Causes, consequences, and remedies for growth-induced solid stress in murine and human tumorsProceedings of the National Academy of Sciences, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Novel Role of Base Excision Repair in Mediating Cisplatin CytotoxicityJournal of Biological Chemistry, 2011
- Anti-apoptotic Protein BCL2 Down-regulates DNA End Joining in Cancer CellsJournal of Biological Chemistry, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- The mouse ortholog of NEIL3 is a functional DNA glycosylase in vitro and in vivoProceedings of the National Academy of Sciences, 2010
- Epidemiology of pancreatic cancer: an overviewNature Reviews Gastroenterology & Hepatology, 2009
- Bcl2 Negatively Regulates DNA Double-Strand-Break Repair through a Nonhomologous End-Joining PathwayMolecular Cell, 2008